The Latest Breaking News from JNJ

With a strong product portfolio and growth prospects in innovative medicines, this dividend stock is likely to maintain its 63-year streak of dividend increases.

Johnson Johnson (NYSE:JNJ) is reportedly halting international sales of its Linx Reflux Management System, a device used to treat chronic acid reflux.

Despite ongoing legal battles related to its talc products, Johnson Johnson (NYSE:JNJ) stock has climbed over 23% year-to-date.

On Tuesday, the U.S. Food and Drug Administration (FDA) approved Johnson Johnson's (NYSE:JNJ) Inlexzo (gemcitabine intravesical system) as a new treatment approach for certain types of bladder cancer patients who need additional options following unsuccessful BCG therapy and for patients refusing or ineligible for bladder removal surgery (radical cystectomy).

Johnson Johnson (NYSE:JNJ) on Tuesday won regulatory approval for its drug delivery product Inlexzo to treat high-risk non-muscle invasive bladder cancer, a milestone Goldman Sachs says could launch “a powerful new product cycle” for the company's TAR-200 program.

Johnson Johnson (NYSE:JNJ) reported new cardiovascular data at the 2025 European Society of Cardiology Congress.

Johnson Johnson (NYSE:JNJ) on Thursday shared topline data from the Phase 2a DAISY proof-of-concept study evaluating the combination of nipocalimab with an anti-tumor necrosis factor alpha (anti-TNFα) therapy in rheumatoid arthritis (RA) patients with refractory disease.

Johnson & Johnson has significantly outperformed other healthcare stocks over the past year, and analysts remain moderately bullish on the stock’s prospects.

Procter & Gamble, PepsiCo, and Johnson & Johnson stand out as dividend growth leaders with upside potential into year-end